Several structurally different CatS inhibitors were shown to be effective in either a psoriatic or an atopic dermatitis mouse model but only one CatS (VBY-891) inhibitor successfully passed a phase I safety study for psoriasis, and the study discontinued after the phase II efficacy phase [33]. This evidence concerns the gene PIMREG and atopic eczema.